Diabetes and dementia: a common link or coincidental coexistence? by Manning, Stephen R.
Received 8 November 2007, accepted 10 December 2007. 
Correspondence and reprint request to Dr Stephen R. Manning, 11 Pinewood Close, Yew Tree Estate, Walsall, W. Midlands, 
WS5 4JR, UK. Tel.: 44 7866 859 959, E-mail: stephen_manning@lycos.co.uk
© Bulgar ian Society for Cell Biology
ISSN 1310-392X
INTRODUCTION
On 3 November 1906 in Munich, the neuropathologist Alois 
Alzheimer first reported the presence of (i) neurofibrillary
tangles in neurons of the cortex and hippocampus, and (ii) 
extracellular cerebral deposits of amyloid in “presenile demen-
tia”, later identified asAlzheimer’s disease, a catastrophic brain
damage leading to loss or decline in memory and other cogni-
tive abilities. Dementia is a common problem affecting older 
persons. In the UK alone, it is estimated that nearly 700,000 
people have dementia, while worldwide this figure approaches
30 million individuals, including patients with Alzheimer’s 
disease (1). The direct and indirect coasts of Alzheimer’s and 
other dementias in the United States amount to more than 148 
billion dollars each year. Over 2 million of the United King-
dom population are diagnosed with diabetes mellitus, type 2 
diabetes being a prominent expression of the disease.
 Over the last few years, a large number of articles have 
drawn attention to the association between dementia and type 
2 diabetes mellitus. A causative link between Alzheimer’s 
disease and diabetes has been suggested based on clinical 
and epidemiological studies. One hypothesis is that the link is 
related to the function of insulin-degrading enzyme, an enzyme 
that degrades not only insulin and pancreatic amylin but also 
amyloid-beta peptide (Abeta) (2). A systematic review of 25 
longitudinal studies of cognitive function changes related to 
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diabetic status found that compared to non-diabetics, diabetics 
have both a greater risk and rate of cognitive decline (3). A 
study of a further 19 case-control studies examining cognitive 
function in type 2 diabetes came to the cautious conclusion 
that cognitive decline in diabetics may be due to metabolic 
abnormalities intrinsic to diabetes (4). A further systematic 
review of longitudinal population based studies has also found 
that any form of dementia is more frequent in diabetics and 
proposed 3 broad potential causes: vascular disease, alterations 
in glucose and insulin, and alterations in amyloid metabolism 
(5).
 Taken together, these studies give strong support to the ob-
servation that cognitive decline is more common in diabetic 
compared to non-diabetic subjects. Naturally, this makes us 
ask ourselves; why should this be? Let us look briefly at the
3 potential causes proposed above and one other which may 
provide a link between all 3 – cholesterol.
VASCULAR DISEASE
Diabetes can be considered as a cardiovascular (cardiometa-
bolic) disease, the risk of atherosclerotic disease being higher 
in diabetic versus non-diabetic patients. Higher than optimum 
blood glucose levels is a leading cause of cardiovascular mor-
tality in terms of ischaemic heart disease and also stroke (6). 
Meta-analysis has shown that attempts to improve glycaemic 
control also reduce macrovascular complications of diabetes 
(7). Vascular dementia is a common cause of dementia in the 
elderly, second only to Alzheimer’s disease. It is defined as loss
of cognitive function resulting from ischaemic, hypoperfusive, 
or hemorrhagic brain lesions due to cerebrovascular disease. 
A large clinical trial is currently under way to assess whether 
intensive treatment of diabetes can reduce the incidence of 
either Alzheimer’s disease or vascular dementia (8). Vascular 
dementia and Alzheimer’s disease both give rise to dementia, 
however they have distinct pathologies. This would suggest 
that vascular changes alone are not sufficient to explain a link
between diabetes and dementia, especially when linked to 
Alzheimer’s disease.
HYPOGLYCAEMIA
Insulin dependant, type 2 diabetics are at an increased risk 
of periods of hypoglycaemia. This risk increases with tighter 
glycaemic control regimes, which at the same time reduce the 
risk of vascular and neuropathic complications of diabetes. 
An inappropriately high insulin level leads to hypoglycaemia. 
The brain relies on glucose as a fuel source. The effects of 
hypoglycaemia upon brain function are profound, revers-
ible and short lived. A large randomised controlled trial, the 
DCCT/EDIC study looked at the effects of tight glycaemic 
control and number of hypoglycaemic events upon cognitive 
function. It was found that the cumulative number of hypogly-
caemic events did not influence long term cognitive function.
However, a higher glycosylated haemoglobin (HbA1c) value, 
indicating poorer glycaemic control was associated with a de-
cline in psychomotor function. This study suggests that while 
acute hypoglycaemia is dangerous, tighter glycaemic control 
in the long term reduces psychomotor function decline as seen 
in less well controlled diabetics (9). It would seem, therefore, 
that hypoglycaemic episodes are not responsible for long term 
cognitive decline.
AMYLOID METABOLISM 
Localised progressive amyloidosis is seen in both Alzheim-
er’s and type 2 diabetes. The formation of neurofibrillary
tangles composed of Abeta and abnormally phosphorylated 
mictotubule-associated tau protein has been well studied in 
Alzheimer’s disease but less so in type 2 diabetes, where amy-
loid accumulation is found in pancreatic islets. In both cases, 
misfolding of insoluble proteins leads to an interaction with 
cell membrane and a loss of normal cell function and ultimately 
cell mass. Both conditions can be considered to be a low grade 
inflammatory reaction associated with the elevation of circu-
lating pro-inflammatory cytokines and acute phase proteins
including serum amyloid A and C-reactive protein. Recently, 
another common player, acetylcholine (Ach), has been intro-
duced into diabetes-dementia link (10,11). Acetylcholine is one 
of the principle neurotransmitters within the human body and 
its brain deficit is a classical feature ofAlzheimer’s disease (1).
Acetylcholine is broken down by Ach esterase (AChE), found 
in high concentrations in nervous tissue. Intriguingly, the activ-
ity of AChE has also been implicated in an anti-inflammatory
pathway (10-13).  Selective inhibition of AChE to increase 
Ach concentration forms the basis of several anti-dementia 
drugs currently available. 
 Acetylcholine is also broken down by the related enzyme 
butyrylcholine esterase (BChE), which is found in the blood, 
pancreas, liver and central nervous system (CNS). In the 
healthy state, AChE predominates over BChE. The enzymes 
differ in their CNS localisation, AChE being localised to the 
neurons while BChE is localised to the glia, endothelial cells 
and neurons. AchE knockout mice are viable, this supports the 
notion that BChE has a key role and can partly compensate 
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for AChE (10,11,13,14).  
 Studies of Alzheimer’s brain tissue have localised BChE 
to neurofibrillary tangles and have shown BChE to attenuate
amyloid formation by interaction with the C terminus of Abeta 
(15).  It has also been found that increasing levels of BChE 
correlate positively with the development of neurofibrillary
tangle and plaque formation (11).  A particular variant of BChE, 
the K-variant (G1615A/Ala539Thr) has been associated with 
Alzheimer’s disease and the development of neurofibrillary
tangles and Abeta, when homozygous; no association has been 
proven with heterozygous allele carriage (16,17).  Selective 
inhibition of BChE in old rats has improved cognitive naviga-
tion (18). There have been recent developments in designing 
specific BChE inhibitors as potential treatment agents for
Alzheimer’s disease, however none have yet reached regular 
clinical use (19-21).
 Despite these interesting hypotheses, at present the evidence 
to support a genetic link between Alzheimer’s disease and 
type 2 diabetes based upon polymorphisms of the BChE gene 
is unclear. One study has found a link between the BChE K 
variant and type 2 diabetes (22), while a larger scale popula-
tion study found that while the K-variant of BChE was not 
associated with type 2 diabetes (23).
COULD CHOLESTEROL BE THE MISSING LINK?
The brain content of cholesterol is high, approximately 2% by 
weight. Circulating cholesterol is tightly bound to lipoproteins 
and its entry to the brain is tightly regulated and enters cells by 
receptor-mediated endocytosis using low-density lipoprotein 
(LDL) receptors. Little cholesterol crosses the blood-brain 
barrier and almost all of the brain’s cholesterol is synthesised 
by the brain itself. A complex biochemical pathway is involved 
in cholesterol synthesis, starting with acetyl co-enzyme A. The 
rate limiting step in this pathway is the synthesis of meval-
onic acid by the enzyme hydroxymethylglutaryl co-enzyme 
A reductase (HMG-CoA Reductase). This enzyme is said to 
be the most highly regulated enzyme in nature and is subject 
to feedback control at both protein and mRNA level from 
cholesterol. Insulin, acting through the phosphorylation of 
cAMP-response element protein has been found to increase 
HMG-CoA reductase activity by 10 fold in rat hepatoma cells. 
Insulin also acts to down regulate two enzymes involved in 
cholesterol breakdown, sterol 27-hydroxylase and cholesterol 
7α-hydroxylase (24).
 Cholesterol is implicated in amyloid formation as cholesterol 
and cholesteryl esters can directly regulate the generation 
of β-amyloid and inhibit its clearance (25). Cholesterol also 
accumulates within amyloid plaques (26) and binds directly 
to both β-amyloid and its precursor protein (27). A catalytic 
reaction between β-amyloid and cholesterol produces 7β-
hydroxycholesterol which is extremely toxic to hippocampal 
neurons, the area of the brain responsible for memory (28). 
 In type 2 diabetes, insulin resistance is seen, leading to higher 
levels of circulating insulin. Through its interaction with the 
cholesterol biosynthesis pathway could abnormal patterns of 
insulin secretion be causing an increase in cholesterol within 
the brain leading to increased amyloid formation and destruc-
tion of hippocampal neurons? If this is the case then could 
early type 2 diabetes begin a process of amyloid formation in 
both the brain and pancreas involving cholesterol? 
 The class of anticholesterol drugs known as the “statins” 
(e.g. simvastatin, pravastatin, rosuvastatin) inhibit cholesterol 
synthesis via a competitive inhibition of HMG-CoA reductase. 
Could they be used in the prevention or treatment of Alzheim-
er’s disease? At present the evidence is again lacking. Studies 
are reported to be on going but at present there is no clear evi-
dence for the use of statins as either a therapeutic intervention 
or preventative measure for Alzheimer’s development (29-31). 
In reducing the risk of vascular and atherosclerotic disease a 
role for statins is recognised. A link between vascular disease 
and type 2 diabetes may be found via insulin resistance lead-
ing to an increase in insulin circulation causing an increase in 
cholesterol which deposits in atherosclerotic plaques and also 
encourages amyloid formation. 
 Glucagon like peptide-1 (GLP-1) regulates insulin secretion 
and inhibits glucagon release thus regulating both insulin and 
glucose levels. In addition is has a role in reducing amyloid 
and protecting neural cells from apoptosis; GLP-1 has recently 
been endorsed as a promising new treatment for type 2 diabetes 
(32,33). Again, we await with interest the results of studies into 
possible GLP-1 use in dementia patients. Likewise, the body 
of evidence has to grow and further develop before an opinion 
can be reached on the suggestion that Alzheimer’s disease 
can be viewed as type 3 diabetes mellitus (34-37) as well as 
understanding the association between obesity and dementia 
(38-40). Further, altered, usually decreased, plasma levels 
of the neurotrophins nerve growth factor and brain-derived 
neurotrophic factor are associated with psychiatric disorders, 
such as depression and dementia, and diabetes including the 
metabolic syndrome (41-44).  Overall these may have impor-
tant therapeutic and public health implications.
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CONCLUSION
From the evidence available, diabetes and a general cognitive 
decline are associated with each other. Specifically, Alzheim-
er’s disease appears to be associated with type 2 diabetes. The 
nature of this association is not yet clear. Both conditions share 
the pathology of amyloid deposition and loss of cell function, a 
cholinesterase enzyme, common to both brain and pancreas, is 
associated with neurofibrillary tangles and a particular variant
of this enzyme is associated in homozygotes with the develop-
ment of amyloid depositions. Cholesterol is associated with the 
formation of amyloid, and toxicity to hippocampal neurons and 
the synthesis of cholesterol is increased by insulin. However, 
conflicting evidence make these difficult to interpret and their
relationships remain unclear. Other mechanisms of cognitive 
decline include vascular complications of diabetes associated 
with poor glycaemic control. It is possible that both Alzheim-
er’s and vascular dementia can coexist in a person with one or 
the other been the predominant form of cognitive decline.
 At present we are unable to clearly define the link between
Alzheimer’s and diabetes, could we be looking at several 
mechanisms interacting with each other or have we just ex-
amined several small parts of a bigger pathway? Should BchE 
inhibitors come into clinical use, while evaluating their effect 
upon cognitive decline, the progression of diabetes or indeed 
development of diabetes in subjects will be interesting to ob-
serve. As studies continue into the use of statins in the preven-
tion and treatment of Alzheimer’s disease we have to wait for 
the results with cautious optimism. Likewise, we must await 
other studies involving agonists of peroxisome proliferator-
activated receptors gamma, the known insulin sensitizers and 
anti-inflammatory drugs (37). The clinical use if GLP-1 will
also help our understanding into these complex relationships. 
Research into this topic has generated as many questions as 
is has answers. Likewise, studies are required to pursuit an 
eventual link between diabetes and other, non-Alzheimer’s 
types of dementias such as vascular dementia, dementia with 
Lewy bodies, Parkinson’s disease, mild cognitive impairment, 
and even Creutzfeldt-Jakob disease (insulin-prion protein as-
sociation?).
 As Robert Frost would tell us, while we dance round in our 
ring and suppose, the link between diabetes and dementia stays 
firmly in the middle and knows.
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